{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-016082","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2022-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.527203+00:00","generated_at":"2026-06-24T22:32:30.507310+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Diffusion Pharma reports positive Altitude Trial results for TSC; appoints Raven Jaeger as CRO","bullets":["TSC 2.5 mg/kg dose showed positive effects on pH (p<0.1 vs placebo) and lactate at end of exercise under simulated 15,000 ft hypoxia.","Post-exercise recovery improved for pH, lactate, and oxygen saturation (SpO2) at 10 minutes with 2.5 mg/kg dose.","TSC was safe and well tolerated with no serious adverse events across all doses.","Results support planned Phase 2 Hypoxic Tumor Trial initiation in H2 2022; discussions with FDA ongoing.","Employment agreement for CRO Raven Jaeger effective May 18, 2022 includes severance of 1.5x base salary + bonus upon change of control and 12-month non-compete."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-016082","json":"https://secwatch.observer/filing/0001437749-22-016082.json","markdown":"https://secwatch.observer/filing/0001437749-22-016082.md","text":"https://secwatch.observer/filing/0001437749-22-016082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/0001437749-22-016082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/dffn20220627_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:32:30.507310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5fbe16620","claim":"Raven Jaeger was appointed as Chief Regulatory Officer at CervoMed Inc..","evidence_excerpt":"As previously disclosed, on May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/0001437749-22-016082-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Regulatory Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}